Clearside Biomedical gets Nasdaq MVLS deficiency notice; stockholders approve reverse stock split

Clearside Biomedical, Inc.

Received Nasdaq notice on Aug 28, 2025 for non-compliance with $50M MVLS requirement for continued listing on Global Market.
Company has 180 days until Feb 24, 2026 to regain compliance; may consider transfer to Nasdaq Capital Market.
At special meeting Aug 29, 2025, stockholders approved reverse stock split in range of 1-for-5 to 1-for-15 to address bid price deficiency.
Reverse stock split approved with 46.5M for, 2.2M against, 459k abstained out of 49.2M shares present.

item 3.01item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.